The placebo effect in early-phase glaucoma clinical trials

Area of Science:

• Ophthalmology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• The placebo effect, a phenomenon where a patient's symptoms improve after receiving a treatment with no therapeutic effect, is well-documented across various medical fields.
• In glaucoma clinical trials, understanding the magnitude of the placebo effect is crucial for accurately assessing the efficacy of new therapeutic agents.

Purpose of the Study:

• To quantify the extent and prevalence of the placebo effect observed in early-phase clinical studies of glaucoma medications.
• To analyze how the placebo effect might influence the interpretation of treatment efficacy in glaucoma research.

Main Methods:

• A systematic review of Phase I and II clinical trials for glaucoma medications approved after 1977 was conducted.
• Studies were included if they featured a placebo control arm and enrolled patients diagnosed with glaucoma.
• Data on intraocular pressure (IOP) changes in the placebo groups were extracted and analyzed.

Main Results:

• Twenty-three studies, involving 1703 patients and evaluating 10 different glaucoma medications, were included in the analysis.
• In studies measuring IOP at 8 AM, the average decrease in the placebo group was 2.3 ± 1.6 mm Hg (9% reduction).
• For diurnal curve assessments, the mean IOP decrease in placebo groups was 1.4 ± 1.1 mm Hg (6% reduction), with 4 out of 17 studies showing a greater than 2 mm Hg IOP reduction.

Conclusions:

• A placebo effect is a frequent occurrence in early-phase glaucoma clinical trials.
• The presence and magnitude of this placebo effect may pose challenges in definitively evaluating the efficacy of novel glaucoma treatments.